Your session is about to expire
← Back to Search
procalcitonin for Bacterial Pneumonia (ProSAVE Trial)
N/A
Waitlist Available
Led By Michael K Mansour, MD, PhD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights
Summary
This trial will compare PCT-guided antibiotic prescription (by a Stewardship Team) to standard guidelines, in hospitalized adult patients with suspected or confirmed LRTI.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Primary objective
Short treatment of pneumonia
Secondary outcome measures
Antibiotic exposure at discharge
Composite safety adverse event rate
Days of therapy per 1000 patient days
+2 moreOther outcome measures
Clostridium difficile infection (CDI)
Healthcare economic endpoints
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Procalcitonin algorithm+stewardship teamExperimental Treatment1 Intervention
antibiotic prescription guided by PCT values
Group II: standard groupActive Control1 Intervention
standard of care guided by current guidelines
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
procalcitonin
2010
N/A
~760
Find a Location
Who is running the clinical trial?
B·R·A·H·M·S GmbH , part of Thermo Fisher ScientificUNKNOWN
Massachusetts General HospitalLead Sponsor
2,993 Previous Clinical Trials
13,230,021 Total Patients Enrolled
2 Trials studying Bacterial Pneumonia
325 Patients Enrolled for Bacterial Pneumonia
Michael K Mansour, MD, PhDPrincipal InvestigatorMassachusetts General Hospital
Share this study with friends
Copy Link
Messenger